T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. - Wikidata - wikimedia - TriplyDB

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

http://www.wikidata.org/entity/Q34107156

about

The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases Fate mapping of IL-17-producing T cells in inflammatory responses CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity Unexpected protective role for Toll-like receptor 3 in the arterial wall Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out Biomarkers of therapeutic response in multiple sclerosis: current status NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-γ-IL-27 axis.Lithium controls central nervous system autoimmunity through modulation of IFN-γ signaling No quiet surrender: molecular guardians in multiple sclerosis brain Multiple Sclerosis and T Lymphocytes: An Entangled Story Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis Type I Interferons Induce T Regulatory 1 Responses and Restrict Humoral Immunity during Experimental Malaria Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System.Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity.T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?Neuroimaging in multiple sclerosis: neurotherapeutic implications.An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Regulatory effects of IFN-β on the development of experimental autoimmune uveoretinitis in B10RIII mice.Tim-3 and its role in regulating anti-tumor immunity.Deficiency of the G protein Gαq ameliorates experimental autoimmune encephalomyelitis with impaired DC-derived IL-6 production and Th17 differentiation The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation.Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease.Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis.Interferon-β exacerbates Th17-mediated inflammatory disease.Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells.Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population.Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

P2860

Q24594675-1F5D4312-C789-4D3E-9E18-3D66FF39CE9B Q24621244-D93F1B19-B834-4073-92D5-948985B6542C Q24621645-328BB7C4-DF07-40E3-84D3-D3CC6511D6A4 Q24624935-73F4FD22-48EB-4ADD-BCDC-25E78B020706 Q26768649-87E9EC68-BC25-44FD-8206-281D0E7896FF Q26781518-631B6DC4-89EE-490A-BF61-6FA69A172183 Q27012726-4A12F8FA-8380-479D-8780-62900FD0754B Q27308853-017180B5-F1D9-453E-ACC9-52A1D8722A7D Q27324211-ACAB47E1-A3AA-4A32-B5D7-A303288CEE37 Q28084633-98EBA357-7100-4D3C-A3BF-D6BB366950EB Q28086853-007A12D8-7915-4DEF-880A-38847DFDBD59 Q28251763-DC77FC9A-740E-4DCA-A1C6-F9F59FD439AC Q28554673-AB087E4F-7CE1-4CCD-8D20-320F6DB56D6E Q28740839-1F4ABBA6-3FFF-46EC-9508-82186A6E7D1A Q28744592-7ADE73D8-86D6-48C5-AB40-79C0827A33B0 Q30252405-FE7A908A-36C4-44F7-9629-661800B41099 Q30412083-3892984A-7A90-4E25-BF5E-96EC5EE17F3F Q33651898-2546A514-A184-4E83-8CF3-BBC57D7866E9 Q33685904-735AECAA-04A1-446F-9CC2-DEF2B5885C60 Q33765598-2D896A6A-2E2C-4434-8B93-44257CB4A85E Q33806032-940F1F5B-ADE0-45CE-9ED0-81BCFDA4B468 Q33828361-10619E1D-708E-40B5-A705-30B5D527013B Q33855341-3396BE88-9AB1-43C8-BBD5-DAD38536D640 Q33881977-9706E80D-B5C3-46AF-BAF7-EC7D4E538037 Q33900485-C833056C-F81A-4CD3-87E0-E43F3C597A1A Q33909020-6B10EB32-CA64-4F97-BF6A-B9209C992500 Q33920152-B56BD196-0BBE-46C7-B975-3B477FE1820F Q33927253-DBA0495E-D859-41D5-A413-230BA3E31A7A Q33961542-40F0902F-A3D9-4070-A67D-ECCA37BFC00B Q33988240-101DD915-49DE-4FBB-9F93-A639C8BF2378 Q33988247-E353C154-46DC-4FDB-AAF2-F8E12FC05D82 Q34053077-728DE5F3-B558-45CF-81C9-D39BC1DBF5D8 Q34089188-5B156ADA-3904-446B-BEB1-975D703733F8 Q34105985-00282E17-EB45-4A90-A895-4F3A272DD1BF Q34181184-E1B1CC5C-DD87-4EDE-B7DB-FD415ECC910E Q34182445-5CF512E7-A44C-4847-BB43-FB68503D021F Q34215390-EABD9A90-A53D-4EB9-931C-8BD6C751B01A Q34219132-2CA3EB5B-F7C4-4E95-BD10-9B29A0011469 Q34298635-07E46361-4329-4C46-AF1E-580578722FFE Q34355672-36FDA91A-D620-4E46-9F96-15E593ABF410

P2860

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

http://www.wikidata.org/entity/Q34107156

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@ast

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@en

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@nl

type

label

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@ast

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@en

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@nl

prefLabel

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@ast

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@en

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@nl

P1433

Q34107156-C63AFF1E-EE72-459C-83E9-B7961E7208D6

P1476

Q34107156-A9B9D6C1-E8EB-4C86-BE89-88736FF1B7E0

P2093

Q34107156-02715DC7-D341-4EC0-A992-085484EC33C2

Q34107156-06545678-51CC-4300-8BA0-65EA260526CF

Q34107156-0EC5D7C9-6746-43F7-A35A-FF89D2B7CD1E

Q34107156-1A796912-652C-408E-8272-0B9ED58B2AB8

Q34107156-1EF7207D-C6DC-4776-8148-F9126EAAA453

Q34107156-50D0A956-C1F5-4DBE-B91C-E994D32EB749

Q34107156-5825F26A-3D46-45C6-854F-C1974CE6259F

Q34107156-5CF27F66-9527-490E-A206-58A6C06BC433

Q34107156-8CF6C95A-B09F-4B6D-83E1-957C927145FA

Q34107156-A033F956-D567-46EE-852C-FE7D8F193A6D

P2860

Q34107156-14E413A1-E6E2-4152-AB0D-DF64286D525F

Q34107156-180A8190-0C59-4BE0-9259-07BBED2CBB77

Q34107156-519B0CA5-136A-4AF4-B454-E948B41DAC5D

Q34107156-70B88B3A-0BE6-4F1D-A050-53D2B74DFB26

Q34107156-7C0F20F1-1D37-49BB-8B5D-D1D6B0C94D7A

Q34107156-84383226-BE64-4F31-A6D2-EA8ECB942299

Q34107156-8FDD1B31-B52A-4E75-BB9B-8D0B27909FA9

Q34107156-91292B7D-F31B-4B2D-BA0F-EF37341BEF76

Q34107156-915E87A2-DAD5-4C3B-8592-7AB25E62712F

Q34107156-97D57190-F5FD-4AAF-94FF-965EFA3E02EF

P2888

Q34107156-73D85953-2DB8-47FB-973C-A633C96C604A

P304

Q34107156-2EB69749-A099-49F8-8D36-8B5BF14DAE10

P31

Q34107156-8C9E33D8-BD0C-4D22-8763-620B6B638B82

P356

Q34107156-7418227C-2640-4792-8752-7B4D13ED1216

P407

Q34107156-135CFF93-E46C-481F-B10F-4A9DD83865CD

P433

Q34107156-CC049A16-B373-4D5A-9C94-134FDBA8F70E

P478

Q34107156-DD5A651A-F3FB-40E4-BD0B-C395322F6D48

P50

Q34107156-943411D0-330E-4C91-958C-0FECE7EB1CA4

Q34107156-CE84851A-8925-4AB9-92F6-52F9574D6B01

P577

Q34107156-AC2E2EC1-6C93-496B-8154-EE23095AC9E1

P5875

Q34107156-11D3F170-FD1E-42D3-ADA8-4E4368E148B2

P6179

Q34107156-DC7C2145-D733-4F5D-BD69-B0D4CF7B98E9

P698

Q34107156-662C9306-7BA7-4EF2-81D5-E95DF7A92613

P921

Q34107156-9A4DCCFB-DFE0-41B5-8B5C-4AD49EAA419C

P932

Q34107156-4FBA708D-FDA3-4B45-9556-B3CC35CDE336

P356

P1433

Nature Medicine

P1476

T helper type 1 and 17 cells d ...... xperimental encephalomyelitis.

@en

P2093

Athena Christakos

http://www.w3.org/2001/XMLSchema#string

Brigit A de Jong

http://www.w3.org/2001/XMLSchema#string

Chander Raman

http://www.w3.org/2001/XMLSchema#string

Chris H Polman

http://www.w3.org/2001/XMLSchema#string

Franklin Zhong

http://www.w3.org/2001/XMLSchema#string

Ilan Kolkowitz

http://www.w3.org/2001/XMLSchema#string

Jim G Castellanos

http://www.w3.org/2001/XMLSchema#string

Joep Killestein

http://www.w3.org/2001/XMLSchema#string

Laura F van der Voort

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

P2860

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo

Cluster analysis and display of genome-wide expression patterns

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Transforming growth factor-beta induces development of the T(H)17 lineage

Mechanisms of type-I- and type-II-interferon-mediated signalling

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice.

P2888

P304

406-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2110

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

René de Waal Malefyt

P577

2010-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42611433

http://www.w3.org/2001/XMLSchema#string

P6179

1053047527

http://www.w3.org/2001/XMLSchema#string

P698

20348925

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3042885

http://www.w3.org/2001/XMLSchema#string